Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Adjustment of pharmacotherapy during the final days of life in home hospice care: a pilot retrospective study

M. Novosadová, S. Filip, V. Molnárová, A. Michlová, J. Hrubešová, J. Novosad

. 2025 ; 14 (2) : 136-145. [pub] -

Jazyk angličtina

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc25016367

BACKGROUND: Effective end-of-life care requires transitioning pharmacotherapy from chronic disease management to symptom relief. Patients in pre-terminal and terminal palliative care may be at risk of receiving potentially inappropriate drugs regarding indication, dosage, route of administration, and polypharmacy, which can increase the risk of deteriorating quality of life. However, data on this process in Home Hospice Care (HHC) is limited. This pilot retrospective study evaluated the pharmacotherapy of 50 patients during their final days under HHC, focusing on changes in treatment and preferred administration routes to optimize symptomatic care. METHODS: Anonymised medical records data were analysed retrospectively to assess the shift from chronic disease pharmacotherapy to symptom and quality-of-life-focused treatment. Statistical methods were applied to identify trends in drug utilisation and administration routes. RESULTS: The study group qualified the most common drugs associated with potential drug-related problems: antidepressants (26%), sedatives/hypnotics (32%), gastroprotection (34%), antihypertensives (46%), coanalgesics (50%), and analgesics (84%). On the final day, the mean was 2.64 systemic medication (standard deviation 1.27), with a minimum number of drugs and a maximum of 6. The most common symptom addressed was pain, which occurred in 28 patients in the group (56%). Therefore, terminal analgosedation was mapped in more detail when, at the end of life, 26 patients (52%) were terminally transferred to continuous medication administered subcutaneously. Continuous subcutaneous linear driver for analgosedation containing two components was used in 12 patients (46.2%) or three components in 14 patients (53.8%). CONCLUSIONS: This retrospective study highlights the importance of targeted pharmacotherapy adjustments in terminal care, including multidisciplinary HHC teams. Pharmacotherapy is simplified and targeted to prevalent symptoms, using the widely used subcutaneous drug administration.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc25016367
003      
CZ-PrNML
005      
20250731092845.0
007      
ta
008      
250708s2025 cc f 000 0|eng||
009      
AR
024    7_
$a 10.21037/apm-24-146 $2 doi
035    __
$a (PubMed)40211739
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a x
100    1_
$a Novosadová, Martina $u Hospital Pharmacy, Department of Clinical Pharmacy, University Hospital Hradec Kralove, Hradec Kralove, Czech Republic; Department of Supportive and Palliative Care, University Hospital Hradec Kralove, Hradec Kralove, Czech Republic
245    10
$a Adjustment of pharmacotherapy during the final days of life in home hospice care: a pilot retrospective study / $c M. Novosadová, S. Filip, V. Molnárová, A. Michlová, J. Hrubešová, J. Novosad
520    9_
$a BACKGROUND: Effective end-of-life care requires transitioning pharmacotherapy from chronic disease management to symptom relief. Patients in pre-terminal and terminal palliative care may be at risk of receiving potentially inappropriate drugs regarding indication, dosage, route of administration, and polypharmacy, which can increase the risk of deteriorating quality of life. However, data on this process in Home Hospice Care (HHC) is limited. This pilot retrospective study evaluated the pharmacotherapy of 50 patients during their final days under HHC, focusing on changes in treatment and preferred administration routes to optimize symptomatic care. METHODS: Anonymised medical records data were analysed retrospectively to assess the shift from chronic disease pharmacotherapy to symptom and quality-of-life-focused treatment. Statistical methods were applied to identify trends in drug utilisation and administration routes. RESULTS: The study group qualified the most common drugs associated with potential drug-related problems: antidepressants (26%), sedatives/hypnotics (32%), gastroprotection (34%), antihypertensives (46%), coanalgesics (50%), and analgesics (84%). On the final day, the mean was 2.64 systemic medication (standard deviation 1.27), with a minimum number of drugs and a maximum of 6. The most common symptom addressed was pain, which occurred in 28 patients in the group (56%). Therefore, terminal analgosedation was mapped in more detail when, at the end of life, 26 patients (52%) were terminally transferred to continuous medication administered subcutaneously. Continuous subcutaneous linear driver for analgosedation containing two components was used in 12 patients (46.2%) or three components in 14 patients (53.8%). CONCLUSIONS: This retrospective study highlights the importance of targeted pharmacotherapy adjustments in terminal care, including multidisciplinary HHC teams. Pharmacotherapy is simplified and targeted to prevalent symptoms, using the widely used subcutaneous drug administration.
650    _2
$a lidé $7 D006801
650    _2
$a retrospektivní studie $7 D012189
650    _2
$a pilotní projekty $7 D010865
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a senioři $7 D000368
650    12
$a péče v hospici $x metody $7 D017051
650    12
$a služby domácí péče $7 D006699
650    _2
$a senioři nad 80 let $7 D000369
650    _2
$a lidé středního věku $7 D008875
650    12
$a péče o umírající $x metody $7 D013727
650    12
$a paliativní péče $7 D010166
650    _2
$a polypharmacy $7 D019338
650    _2
$a kvalita života $7 D011788
655    _2
$a časopisecké články $7 D016428
700    1_
$a Filip, Stanislav $u Department of Oncology and Radiotherapy, University Hospital Hradec Kralove, Hradec Kralove, Czech Republic
700    1_
$a Molnárová, Veronika $u Department of Supportive and Palliative Care, University Hospital Hradec Kralove, Hradec Kralove, Czech Republic; Department of Oncology and Radiotherapy, University Hospital Hradec Kralove, Hradec Kralove, Czech Republic
700    1_
$a Michlová, Anna $u Home Hospice Care, Regional Charity Hradec Kralove, Hradec Kralove, Czech Republic
700    1_
$a Hrubešová, Jana $u Clinic of Anesthesiology, Resuscitation and Intensive Medicine, University Hospital Hradec Kralove, Hradec Kralove, Czech Republic
700    1_
$a Novosad, Jakub $u Institute of Clinical Immunology and Allergy, University Hospital Hradec Kralove, Hradec Kralove, Czech Republic
773    0_
$w MED00195445 $t Annals of palliative medicine $x 2224-5839 $g Roč. 14, č. 2 (2025), s. 136-145
856    41
$u https://pubmed.ncbi.nlm.nih.gov/40211739 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20250708 $b ABA008
991    __
$a 20250731092839 $b ABA008
999    __
$a ok $b bmc $g 2366902 $s 1253492
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2025 $b 14 $c 2 $d 136-145 $e - $i 2224-5839 $m Annals of palliative medicine $n Ann Palliat Med $x MED00195445
LZP    __
$a Pubmed-20250708

Najít záznam

Citační ukazatele

Možnosti archivace